Loading drug development pipeline…
Loading drug development pipeline…
Derived
For each drug, the most advanced stage supported by registered interventional trials and jurisdiction-aware approval records. Approval in any ingested jurisdiction outranks trial phase; a drug is counted once, at its highest stage.
Computedci-drug-pipeline-v1Stage rulesApprovals feed →
Funnel
Drugs reach Malignant Gallbladder Neoplasm through trial conditions or approval indications mapped to it or to one of its descendant entities.
0 drugs · 0 active trials
no drug at this stage
0 drugs · 0 active trials
no drug at this stage
Data updated 7 hours agoSource updated unknownrecomputed with the intelligence layer
Drugs
Most advanced stage first, then most active trials. Trial counts are interventional studies linking the drug (and, when a cancer is selected, the cancer).
| Drug | Stage | Max phase | Active | Recruiting | Phase 3 | Total trials | Approvals | Jurisdictions | First approval | First trial |
|---|---|---|---|---|---|---|---|---|---|---|
| Seribantumab | Phase 2 | Phase 2 | 0 | 0 | 0 | 1 | 0 | — | — | Sep 29, 2020 |
| Tegafur | Phase 2 | Phase 2 | 0 | 0 | 0 | 1 | 0 | — | — | Aug 10, 2018 |
| Tislelizumab | Phase 2 | Phase 2 | 0 | 0 | 0 | 1 | 0 | — | — | 2023-11 |
| Trametinib | Phase 2 | Phase 2 | 0 | 0 | 0 | 1 | 0 | — | — | 2014-02 |
| Vandetanib | Phase 2 | Phase 2 | 0 | 0 | 0 | 1 | 0 | — | — | 2008-10 |
| Guadecitabine | Phase 1 | Phase 1 | 1 | 0 | 0 | 1 | 0 | — | — | Feb 7, 2018 |
| Epirubicin | Phase 1 | Phase 1 | 0 | 0 | 0 | 1 | 0 | — | — | Oct 1, 2004 |
| Pralsetinib | Phase 1 | Phase 1 | 0 | 0 | 0 | 1 | 0 | — | — | Oct 2, 2017 |
| Veliparib | Phase 1 | Phase 1 | 0 | 0 | 0 | 1 | 0 | — | — | 2011-01 |
Stages describe registered activity and ingested regulatory records, not efficacy. Only ingested jurisdictions (currently US and Canada) can place a drug at "approved"; trial phases are as registered by sponsors. Nothing here is a treatment recommendation.